Unknown

Dataset Information

Budget Impact Analysis of the Introduction of Rituximab and Trastuzumab Intravenous Biosimilars to EU-5 Markets.


ABSTRACT:

Background

Biologic treatments impose a large financial burden on healthcare payers. Subcutaneous formulations of trastuzumab and rituximab offer administration cost savings relative to the intravenous products through reduced preparation and infusion times. However, intravenous biosimilars have the potential to offset administration costs through lower drug costs.

Objective

The objective was to develop a budget impact model (BIM) from a payer's perspective for the EU-5 countries (UK, France, Germany, Spain, Italy) to demonstrate the economic impact of using intravenous trastuzumab and rituximab biosimilars.

Methods

An incidence-based BIM was developed to estimate the net budget impact utilising epidemiology data from the literature, market research data on the use of

SUBMITTER: Jang M 

PROVIDER: S-EPMC7803676 | biostudies-literature | 2021 Jan

REPOSITORIES: biostudies-literature